XVIVO Q2 sales rise 34%, beat estimates on thoracic strength

XVIVO Q2 sales rise 34%, beat estimates on thoracic strength

US concludes third round of strikes against Iran after Trump reinstates blockade Investing.com -- Sweden-based medical technology company XVIVO reported second-quarter net sales of SEK 239 million, surpassing the average analyst estimate of SEK 235.68 million. The company’s net sales increased 34% compared to the same period last year. Organic growth reached 36% in local currencies during the quarter.

The thoracic segment drove the company’s performance with sales rising 53% in local currencies. The abdominal segment also contributed to growth, with sales increasing 26% in local currencies. Services sales declined 25% in local currencies, partially offsetting gains from product sales.

XVIVO reported a net profit of SEK 16.30 million for the quarter, with earnings per share of SEK 0.52. Operating income reached SEK 25 million. The company said it sees growth opportunities across its product portfolio and key markets.

XVIVO expects increasing adoption of its technologies to drive future growth. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.